loading
Lixte Biotechnology Holdings Inc stock is traded at $1.54, with a volume of 1,131. It is up +5.37% in the last 24 hours and down -18.23% over the past month. Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$1.49
Open:
$1.48
24h Volume:
1,131
Relative Volume:
0.00
Market Cap:
$3.40M
Revenue:
-
Net Income/Loss:
$-4.69M
P/E Ratio:
-0.4162
EPS:
-3.7
Net Cash Flow:
$-3.81M
1W Performance:
-1.88%
1M Performance:
-18.23%
6M Performance:
-36.95%
1Y Performance:
-45.10%
1-Day Range:
Value
$1.48
$1.51
1-Week Range:
Value
$1.47
$1.73
52-Week Range:
Value
$1.31
$4.42

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name
Name
Lixte Biotechnology Holdings Inc
Name
Phone
310 203 2902
Name
Address
248 ROUTE 25A, EAST SETAUKET
Name
Employee
4
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
LIXT's Discussions on Twitter

Compare LIXT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LIXT 1.51 3.40M 0 -4.69M -3.81M -3.70
VRTX 445.91 115.74B 10.63B -479.80M -1.35B 13.33
REGN 736.64 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 585.04 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 247.06 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.23 24.49B 3.30B -501.07M 1.03B 11.54

Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News

pulisher
Nov 15, 2024

LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com

Nov 15, 2024
pulisher
Oct 29, 2024

LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 29, 2024
pulisher
Oct 28, 2024

LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 23, 2024

Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com

Oct 23, 2024
pulisher
Oct 09, 2024

Lixte Biotechnology Holdings Inc WT (LIXTW-Q) QuotePress Release - The Globe and Mail

Oct 09, 2024
pulisher
Oct 01, 2024

Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com

Oct 01, 2024
pulisher
Oct 01, 2024

MRVI Stock Drops 5.11% Amid Financial Report Release - GuruFocus.com

Oct 01, 2024
pulisher
Sep 24, 2024

Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 2.1% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy - GlobeNewswire

Sep 24, 2024
pulisher
Sep 23, 2024

Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Liquidia Co. (NASDAQ:LQDA) Shares Bought by Rhumbline Advisers - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Pacer Advisors Inc. Has $16.07 Million Stock Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Renaissance Technologies LLC Sells 2,000 Shares of LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

Texas Permanent School Fund Corp Trims Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Huber Capital Management LLC Acquires 241,814 Shares of Lyft, Inc. (NASDAQ:LYFT) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024
pulisher
Sep 19, 2024

Investors who lost money with shares of Liquidia Corporation - openPR

Sep 19, 2024
pulisher
Sep 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - Kilgore News Herald

Sep 18, 2024
pulisher
Sep 11, 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance

Sep 11, 2024
pulisher
Sep 10, 2024

Biotech Steals The Show Following Pre-Clinical Data Announcement - MSN

Sep 10, 2024
pulisher
Sep 05, 2024

Lixte Biotechnology Holdings Inc (LIXT) Stock: A Year of Decreases and Increases - The InvestChronicle

Sep 05, 2024
pulisher
Sep 04, 2024

LIXTLixte Biotechnology Holdings, Inc. Latest Stock News & Market Updates - StockTitan

Sep 04, 2024
pulisher
Sep 04, 2024

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology - GlobeNewswire

Sep 04, 2024
pulisher
Aug 31, 2024

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World

Aug 31, 2024
pulisher
Aug 28, 2024

Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 28, 2024
pulisher
Aug 27, 2024

Market Recap Check: Lixte Biotechnology Holdings Inc (LIXT)’s Positive Finish at 2.00, Up/Down 11.12 - The Dwinnex

Aug 27, 2024
pulisher
Aug 27, 2024

LIXT Stock: A Voyage Through Lixte Biotechnology Holdings Inc’s Finances - The InvestChronicle

Aug 27, 2024
pulisher
Aug 27, 2024

LIXT stock touches 52-week low at $1.55 amid market fluctuations - Investing.com

Aug 27, 2024
pulisher
Aug 26, 2024

First Patient Dosed with LIXTE’s LB-100 in New Clinical - GlobeNewswire

Aug 26, 2024
pulisher
Aug 26, 2024

First Patient Dosed with Lixte Biotechnology Holdings, Inc.?s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - Marketscreener.com

Aug 26, 2024
pulisher
Aug 26, 2024

First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - StockTitan

Aug 26, 2024
pulisher
Aug 24, 2024

Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India

Aug 24, 2024
pulisher
Aug 20, 2024

LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 20, 2024) - GuruFocus.com

Aug 20, 2024
pulisher
Aug 19, 2024

LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 19, 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

LIXT (Lixte Biotechnology Holdings) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

LIXTE Biotechnology Provides Update On Recent Activities and Developments - ForexTV.com

Aug 19, 2024
pulisher
Aug 19, 2024

LIXT (Lixte Biotechnology Holdings) Purchase Of Investment : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

LIXT (Lixte Biotechnology Holdings) Owner Earnings per Shar - GuruFocus.com

Aug 19, 2024
pulisher
Aug 18, 2024

LIXT (Lixte Biotechnology Holdings) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 18, 2024

LIXT (Lixte Biotechnology Holdings) Debt-to-Equity : 0.00 (As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

LIXT (Lixte Biotechnology Holdings) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

LIXT (Lixte Biotechnology Holdings) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

LIXT (Lixte Biotechnology Holdings) Float Percentage Of Tot - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

LIXT (Lixte Biotechnology Holdings) Interest Coverage : 0 (At Loss) (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

LIXT (Lixte Biotechnology Holdings) Capex-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024

Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):